Cardiovascular Drugs Practice Questions

Q: Enalapril is contraindicated in all of the following conditions except?

Diabetic nephropathy with albuminuria. **Explanation:** **Enalapril**, an ACE inhibitor (ACEi), is not only safe but is the **drug of choice** for **Diabetic Nephropathy with albuminuria**. 1. **Why Option A is correct:** In diabetic nephropathy, ACE inhibitors provide a **renoprotective effect**. They selectively dilate the **efferent arteriole** of the glomerulus, which reduces intraglomerular pressure and decreases protein excretion (albuminuria). This slows the progression of chronic kidney disease (CKD). 2. **Why other options are contraindications:** * **Bilateral Renal Artery Stenosis (and Single Kidney with Stenosis):** In these conditions, glomerular filtration rate (GFR) is maintained by high levels of Angiotensin II, which constricts the efferent arteriole. Giving Enalapril removes this compensatory constriction, leading to a precipitous drop in GFR and **acute renal failure**. * **Hyperkalemia:** ACE inhibitors reduce Aldosterone secretion (which normally promotes potassium excretion). Therefore, they cause potassium retention. Administering them in an already hyperkalemic patient can lead to life-threatening arrhythmias. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** ACE inhibitors are contraindicated in pregnancy as they cause fetal renal anomalies (Potter sequence) and skull hypoplasia. * **Side Effects:** The most common side effect is a **dry cough** (due to increased Bradykinin and Substance P). The most serious side effect is **Angioedema**. * **Monitoring:** When starting an ACEi, always monitor serum creatinine and potassium levels. A rise in creatinine up to 30% is acceptable; beyond that, the drug should be discontinued.

Q: Which drug should not be given in pregnancy?

ACE inhibitors. **Explanation:** **ACE inhibitors (e.g., Enalapril, Lisinopril)** are strictly contraindicated in pregnancy (Category X) because they are potent **teratogens**. Their mechanism involves blocking the Renin-Angiotensin-Aldosterone System (RAAS), which is crucial for fetal renal development. Exposure, particularly in the 2nd and 3rd trimesters, leads to **fetal renal dysgenesis**, which causes oligohydramnios (low amniotic fluid). This results in the **"Potter sequence"** (hypoplastic lungs, limb contractures, and cranial malformations) and fetal skull hypoplasia. **Analysis of Incorrect Options:** * **Methyldopa (Option D):** Historically the "gold standard" and safest drug for chronic hypertension in pregnancy. It is a centrally acting alpha-2 agonist with a long-standing safety profile. * **Labetalol (Option A):** Currently the first-line agent for both chronic hypertension and hypertensive emergencies in pregnancy due to its rapid onset and minimal side effects. * **Hydralazine (Option B):** A direct vasodilator commonly used for the acute management of severe hypertension or pre-eclampsia. **High-Yield Clinical Pearls for NEET-PG:** * **Safe Drugs in Pregnancy:** Remember the mnemonic **"Better Mother Care During Hypertensive-crisis"** (B-Labetalol, M-Methyldopa, C-Nifedipine/CCBs, D-Hydralazine). * **Teratogenic Effect:** ACE inhibitors and ARBs (Angiotensin Receptor Blockers) both cause **renal agenesis** and **skull defects**. * **Diuretics:** Generally avoided in pregnancy as they can decrease uteroplacental perfusion by reducing plasma volume. * **Statins and Warfarin:** Also contraindicated (Warfarin causes Fetal Warfarin Syndrome; Statins are teratogenic).

Q: Which of the following medications can cause cholelithiasis and choledocholithiasis?

Clofibrate. **Explanation:** **Clofibrate** (a first-generation Fibrate) is the correct answer. Fibrates act as **PPAR-α agonists**, which increase the activity of lipoprotein lipase. However, they also inhibit the enzyme **cholesterol 7α-hydroxylase**, which is the rate-limiting step in bile acid synthesis. This leads to: 1. **Decreased bile acid production:** Reducing the solubility of cholesterol in bile. 2. **Increased biliary cholesterol excretion:** Resulting in supersaturation of bile. This combination promotes the formation of cholesterol gallstones (**cholelithiasis**) and their subsequent migration into the common bile duct (**choledocholithiasis**). Due to this significant side effect profile, Clofibrate has largely been replaced by newer fibrates like Fenofibrate. **Incorrect Options:** * **Chloramphenicol:** Primarily associated with bone marrow suppression (dose-dependent) and **Gray Baby Syndrome** (due to deficient glucuronidation in neonates). * **Cotrimoxazole:** Commonly causes hypersensitivity reactions (Stevens-Johnson Syndrome), photosensitivity, and megaloblastic anemia (due to folate antagonism). * **Option D:** This is a clinical condition, not a medication, and does not have a direct causal link to gallstone formation in the context of pharmacological side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Fibrates + Statins:** Combining these increases the risk of **myopathy and rhabdomyolysis** (Gemfibrozil is the worst offender as it inhibits statin glucuronidation). * **Drug of Choice:** Fibrates are the DOC for **Hypertriglyceridemia** (Type IV and V hyperlipoproteinemia). * **Other drugs causing gallstones:** Ceftriaxone (biliary sludge/pseudolithiasis) and Octreotide (inhibits gallbladder contractility).

Q: Ezetimibe acts by

Decreasing absorption of cholesterol. **Explanation:** **Ezetimibe** is a cholesterol absorption inhibitor that specifically targets the **Niemann-Pick C1-Like 1 (NPC1L1)** transport protein located on the brush border of enterocytes in the small intestine. By inhibiting this transporter, it reduces the delivery of dietary and biliary cholesterol to the liver. This leads to an upregulation of LDL receptors on hepatocytes, subsequently decreasing circulating LDL-C levels. **Analysis of Options:** * **Option A (Enhancing excretion of bile acids):** This is the mechanism of **Bile Acid Sequestrants** (e.g., Cholestyramine, Colestipol). They bind bile acids in the gut, preventing enterohepatic circulation and forcing the liver to use cholesterol to synthesize new bile acids. * **Option B (Correct):** Ezetimibe directly inhibits the intestinal absorption of cholesterol. * **Option C (Inhibiting HMG CoA reductase):** This is the mechanism of **Statins** (e.g., Atorvastatin). Statins inhibit the rate-limiting step of endogenous cholesterol synthesis. * **Option D (Inhibiting intracellular lipase):** This refers to the mechanism of **Fibrates** (which stimulate lipoprotein lipase) or **Niacin** (which inhibits hormone-sensitive lipase in adipose tissue). **High-Yield Clinical Pearls for NEET-PG:** * **Synergy:** Ezetimibe is frequently used as an "add-on" therapy to Statins. While Statins inhibit cholesterol *synthesis*, Ezetimibe inhibits cholesterol *absorption*, leading to a potent dual effect. * **Vytorin:** A fixed-dose combination of Ezetimibe + Simvastatin. * **Side Effects:** Generally well-tolerated; however, it may cause a mild increase in hepatic transaminases when used with statins. * **Key Target:** Always remember **NPC1L1** for Ezetimibe; it is a common "one-liner" question in PG exams.

Q: All of the following statements about lignocaine are true EXCEPT:

It is given orally for treatment of cardiac arrhythmias.. ### Explanation **Correct Answer: C. It is given orally for treatment of cardiac arrhythmias.** **Why Option C is the correct answer (The "Except" statement):** Lignocaine (Lidocaine) is a Class IB antiarrhythmic agent that undergoes **extensive first-pass metabolism** in the liver. If administered orally, its bioavailability is extremely low (approx. 30%), and its metabolites (monoethylglycinexylidide) can be toxic to the CNS. Therefore, for systemic effects like treating ventricular arrhythmias (e.g., post-MI), it must be administered **intravenously**. **Analysis of Incorrect Options:** * **Option A:** Lignocaine is a state-dependent sodium channel blocker. It has a higher affinity for **active (open) and inactivated states** of the sodium channel rather than the resting state. This property allows it to selectively block rapidly firing tissues (like ischemic myocardium). * **Option B:** While lignocaine is safer for the heart than bupivacaine, high systemic doses can lead to **cardiotoxicity**, manifesting as bradycardia, hypotension, and arrhythmias. * **Option C:** **Adrenaline (Epinephrine)** is a vasoconstrictor. When added to local anaesthetics for infiltration, it reduces local blood flow, thereby slowing the systemic absorption of lignocaine. This **increases the duration of action** and reduces systemic toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Lignocaine is the DOC for **ventricular arrhythmias** occurring during cardiac surgery or post-Myocardial Infarction. * **CNS Toxicity:** The initial signs of lignocaine toxicity are often neurological (perioral numbness, metallic taste, tremors, and seizures). * **Adrenaline Contraindication:** Never use lignocaine with adrenaline for "end-artery" areas like the **fingers, toes, tip of the nose, or penis**, as it can cause ischemic necrosis/gangrene. * **Metabolism:** It is metabolized by hepatic CYP3A4.

Q: Which of the following drugs acts as both an arteriolar and venodilator?

Sodium nitroprusside. **Explanation:** Sodium Nitroprusside (SNP) is the correct answer because it acts as a **balanced vasodilator**, affecting both resistance vessels (arterioles) and capacitance vessels (veins) [1, 3]. **Mechanism of Action:** SNP is a prodrug that reacts with hemoglobin to release **Nitric Oxide (NO)** [1]. NO activates guanylyl cyclase, increasing intracellular **cGMP**, which leads to dephosphorylation of myosin light chains and subsequent relaxation of smooth muscles in both arteries and veins. * **Arteriolar dilation** reduces Total Peripheral Resistance (Afterload). * **Venodilation** increases venous pooling and reduces venous return (Preload). **Analysis of Incorrect Options:** * **A. Hydralazine:** A direct-acting **pure arteriolar vasodilator** [1, 2]. It has minimal effect on veins, often leading to significant reflex tachycardia. * **C. Minoxidil:** A potent **arteriolar vasodilator** that works by opening ATP-sensitive $K^+$ channels, causing hyperpolarization of smooth muscle cells [1]. It does not affect veins. * **D. Captopril:** While ACE inhibitors do cause both arterial and venous dilation by reducing Angiotensin II and increasing Bradykinin, they are classified primarily as **balanced vasodilators in the context of chronic therapy**. In the specific context of "vasodilator pharmacology" questions, SNP is the classic prototype for immediate, direct-acting balanced dilation. **High-Yield Clinical Pearls for NEET-PG:** 1. **SNP Toxicity:** Prolonged infusion can lead to **Cyanide and Thiocyanate toxicity**. The antidote is **Sodium Thiosulfate** or **Hydroxocobalamin**. 2. **Drug of Choice:** SNP is used in hypertensive emergencies but must be protected from light (it is photosensitive). 3. **Steal Phenomenon:** SNP can cause "Coronary Steal," potentially worsening ischemia in patients with CAD. 4. **Minoxidil Side Effect:** Commonly causes **hypertrichosis** (used topically for alopecia) [1].

Q: All of the following statements about the use of spironolactone in CHF are true EXCEPT:

It affords rapid symptomatic relief in CHF patients.. ### Explanation **Spironolactone** is a potassium-sparing diuretic and a Mineralocorticoid Receptor Antagonist (MRA). In Chronic Heart Failure (CHF), its primary role is not acute diuresis, but rather long-term neurohormonal modulation. **1. Why Option D is the Correct Answer (The False Statement):** Spironolactone is a **weak diuretic**. It acts on the distal part of the nephron where only a small fraction of sodium is reabsorbed. Unlike loop diuretics (e.g., Furosemide), it does not produce rapid diuresis or immediate symptomatic relief from pulmonary edema. Its benefits in CHF are primarily due to its ability to prevent myocardial fibrosis and remodeling, which takes weeks to months to manifest. **2. Analysis of Other Options:** * **Option A:** Spironolactone carries a significant risk of **hyperkalemia**, especially when combined with ACE inhibitors. Therefore, it is initiated at low doses (e.g., 12.5–25 mg/day) with close monitoring of serum potassium and creatinine. * **Option B:** Large-scale trials like **RALES** have proven that adding low-dose spironolactone to standard therapy (ACE inhibitors + Digoxin) significantly reduces mortality and morbidity in patients with NYHA Class III and IV heart failure. This is known as "Aldosterone Escape" blockade. * **Option C:** In cases of "diuretic resistance," adding spironolactone can help overcome refractoriness to thiazides or loop diuretics by blocking the compensatory distal sodium reabsorption. **Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive antagonist of aldosterone at the Mineralocorticoid Receptor (MR) in the late distal tubule/collecting duct. * **Side Effects:** Hyperkalemia and **Gynecomastia** (due to non-specific binding to androgen and progesterone receptors). **Eplerenone** is a more selective MRA with fewer endocrine side effects. * **Key Trial:** RALES trial (Spironolactone); EMPHASIS-HF trial (Eplerenone).

Q: Which of the following agents decreases cardiac afterload?

Nicorandil. **Explanation:** The correct answer is **Nicorandil** because of its unique dual mechanism of action. To understand this, we must distinguish between **preload** (venous return/venous dilation) and **afterload** (systemic vascular resistance/arterial dilation). 1. **Why Nicorandil is correct:** Nicorandil acts as both a **Nitrate-like vasodilator** and a **K+ATP channel opener**. While the nitrate component causes venodilation (reducing preload), the opening of ATP-sensitive potassium channels leads to significant hyperpolarization of vascular smooth muscle cells in the **arterioles**. This results in potent arterial dilation, which directly decreases systemic vascular resistance, thereby **decreasing cardiac afterload**. 2. **Why other options are incorrect:** * **Glyceryl trinitrate (GTN) & Isosorbide dinitrate:** These are organic nitrates that primarily act on the venous capacitance vessels at therapeutic doses. Their main effect is reducing **preload**. While they can cause some arterial dilation at very high doses, their clinical hallmark is venodilation. Therefore, they are not the primary agents for afterload reduction compared to Nicorandil. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Nicorandil is the only drug in this list that targets both preload and afterload. * **Cardioprotection:** It mimics "ischemic preconditioning" by opening mitochondrial K+ATP channels, protecting the myocardium during ischemia. * **Side Effect Alert:** A classic, high-yield side effect of Nicorandil is **persistent mucosal ulcerations** (anal, oral, or GI ulcers). * **Contraindication:** Like other nitrates, it should not be co-administered with Sildenafil (PDE-5 inhibitors) due to the risk of severe hypotension.

Question 1

Enalapril is contraindicated in all of the following conditions except?

Accepted Answer

Diabetic nephropathy with albuminuria

Answer

Single kidney

Answer

Bilateral renal artery stenosis

Answer

Hyperkalemia

Question 2

Which drug should not be given in pregnancy?

Accepted Answer

ACE inhibitors

Answer

Labetalol

Answer

Hydralazine

Answer

Methyldopa

Question 3

Which of the following is the most beta-1 selective antagonist?

Accepted Answer

Bisoprolol

Answer

Acebutolol

Answer

Atenolol

Answer

Metoprolol

Question 4

Which of the following medications can cause cholelithiasis and choledocholithiasis?

Accepted Answer

Clofibrate

Answer

Chloramphenicol

Answer

Cotrimoxazole

Answer

Non-small cell lung cancer associated with AIDS

Question 5

Ezetimibe acts by

Accepted Answer

Decreasing absorption of cholesterol

Answer

Enhancing excretion of bile acids

Answer

Inhibiting HMG CoA reductase

Answer

Inhibiting intracellular lipase

Question 6

All of the following statements about lignocaine are true EXCEPT:

Accepted Answer

It is given orally for treatment of cardiac arrhythmias.

Answer

It blocks active sodium channels with more affinity than resting sodium channels.

Answer

It can cause cardiotoxicity.

Answer

Adrenaline increases the duration of action of lignocaine when used for infiltration anaesthesia.

Question 7

ACE inhibitors should not be used concurrently with which of the following agents?

Accepted Answer

Spironolactone

Answer

Amiloride

Answer

Calcium Channel Blockers (CCB)

Answer

Thiazides

Question 8

Which of the following drugs acts as both an arteriolar and venodilator?

Accepted Answer

Sodium nitroprusside

Answer

Hydralazine

Answer

Minoxidil

Answer

Captopril

Question 9

All of the following statements about the use of spironolactone in CHF are true EXCEPT:

Accepted Answer

It affords rapid symptomatic relief in CHF patients.

Answer

It should be administered in low doses to prevent hyperkalemia.

Answer

It affords prognostic benefit in severe heart failure over and above that afforded by ACE inhibitors.

Answer

It helps to overcome the refractoriness to thiazides.

Question 10

Which of the following agents decreases cardiac afterload?

Accepted Answer

Nicorandil

Answer

Glyceryl trinitrate

Answer

Isosorbide dinitrate

Answer

None of the above

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?